- In patients with low-/intermediate-risk prostate cancer (PCa), stereotactic body radiotherapy (SBRT) is associated with low rates of severe adverse events (AEs) and high rates of long-term biochemical control.
Why this matters
- National Comprehensive Cancer Network (NCCN) recommends SBRT as an alternative to conventionally fractionated regimens, but data on long-term effects are unknown.
- Study of individual patient data from 12 phase 2 trials including 2142 men with low-/intermediate-risk prostate cancer.
- Funding: None reported.
- Median follow-up, 6.9 years.
- 55.3% had low-risk disease, 32.3% had favorable intermediate-risk disease, and 12.4% had unfavorable intermediate-risk disease.
- 7-year cumulative rates of biochemical recurrence:
- low-risk disease: 4.5% (95%CI, 3.2%-5.8%),
- favorable intermediate-risk disease: 8.6% (95%CI, 6.2%-11.0%),
- unfavorable intermediate-risk disease: 14.9% (95%CI, 9.5%-20.2%), and
- all intermediate-risk disease: 10.2% (95% CI, 8.0%-12.5%).
- 7-year cumulative incidence of late grade ≥3 genitourinary and gastrointestinal AEs was 2.4% and 0.4%.
- The crude incidence of acute grade ≥3 AEs:
- Gastrointestinal: 0.09%.
- Genitourinary: 0.60% (urinary frequency was most common).
- Lack of comparator group.